{"id":"W4400272924","doi":"10.1200/jco.2024.42.16_suppl.tps4203","title":"Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Medicine; FOLFIRINOX; Atezolizumab; Pancreatic ductal adenocarcinoma; Oncology; Internal medicine; Open label; Stage (stratigraphy); Pancreatic cancer; Randomized controlled trial; Oxaliplatin; Cancer; Nivolumab; Colorectal cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002217907,0.00334438,0.002874862,0.0005782529,0.0005064117,0.001479317,0.001270229,0.002055713,0.006602723],"category_scores_gemma":[0.001249391,0.001018341,0.001732216,0.0005552642,0.001620875,0.002208299,0.0006438473,0.003678341,0.001615901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001380021,"about_ca_system_score_gemma":0.001889706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001181827,"about_ca_topic_score_gemma":0.002623108,"domain_scores_codex":[0.9993775,0.0002946212,0.00001906854,0.0001204792,0.00005046585,0.0001378605],"domain_scores_gemma":[0.999211,0.000114321,0.0001544806,0.00007973699,0.0000499066,0.0003905258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9403986,0.02810536,0.001701223,0.0003877816,0.0006429724,0.00008013853,0.0001023503,0.0008416129,0.006666459,0.0001723252,0.001666847,0.01923439],"study_design_scores_gemma":[0.8478051,0.1474365,0.002370375,0.00001396558,0.0001773724,0.000065784,0.0000318447,0.0004529643,0.0005795295,0.0001598163,0.0008892854,0.0000174869],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854246,0.001868583,0.0008686779,0.0008042251,0.000317368,0.006474094,0.00187781,0.0002198057,0.002144805],"genre_scores_gemma":[0.9711645,0.002079411,0.003579436,0.002099176,0.0005376314,0.009801179,0.004466987,0.00009761366,0.006174079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006602723,"threshold_uncertainty_score":0.02208835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08772171573927955,"score_gpt":0.4636311883234602,"score_spread":0.3759094725841807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}